Comorbidities Remission After Roux-en-Y Gastric Bypass for Morbid Obesity is Sustained in a Long-Term Follow-up and Correlates with Weight Regain.

15:10 EDT 3rd August 2015 | BioPortfolio

Summary of "Comorbidities Remission After Roux-en-Y Gastric Bypass for Morbid Obesity is Sustained in a Long-Term Follow-up and Correlates with Weight Regain."


BACKGROUND:
Obesity-related comorbidities are treated by Roux-en-Y gastric bypass (RYGB) due to weight loss and intestinal hormone changes. Few studies report the evolution of these comorbidities in a long-term follow-up, especially if weight regain is present. This study aims to analyze: (1) the resolution of obesity-related comorbidities after RYGB in a long-term follow-up and (2) its relationship to weight regain.
METHODS:
A retrospective study was conducted on 140 patients submitted to RYGB for morbid obesity for at least 5 years (mean follow-up 90 months). Mean body mass index (BMI) before operation was 52 kg/m(2), at nadir weight 29 kg/m(2), and at last follow-up 33 kg/m(2). The comorbidities diabetes, cardiovascular disease, arterial hypertension, dyslipidemia, sleep apnea, arthropathy, and infertility were classified as resolved, improved, unchanged, and worsened at nadir weight that happened between the first and second year and after five or more years of surgery. For each comorbidity, we compared the changes in the distribution of patients in the categories and the correlation of it with weight loss at the nadir and final weight.
RESULTS:
BMI was significantly different in the three periods. Comorbidities resolution was sustained in a long-term follow-up for diabetes, hypertension, cardiovascular disease, and infertility. Comorbidities status was directly related to the weight loss for all comorbidities except infertility.
CONCLUSIONS:
Our results show that comorbidities remission after RYGB is sustained in a long-term follow-up. Weight regain is linked to worse results for all comorbidities except infertility.

Affiliation

Department of Surgery, Escola Paulista de Medicina, Federal University of São Paulo, São Paulo, Brazil, rmelillo@uol.com.br.

Journal Details

This article was published in the following journal.

Name: Obesity surgery
ISSN: 1708-0428
Pages:

Links

PubMed Articles [4750 Associated PubMed Articles listed on BioPortfolio]

Treatment of giant hiatal hernia by laparoscopic Roux-en-Y gastric bypass.

Obesity is a risk factor for hiatal hernia. In addition, much higher recurrence rates are reported after standard surgical treatment of hiatal hernia in morbidly obese patients. Laparoscopic Roux-en-Y...

Metabolic syndrome resolution by Roux-en-Y gastric bypass in a real world: a case control study.

the aim of this study was to evaluate the efficacy of Roux-en-Y Gastric Bypass (RYGB), compared with nonsurgical treatment (NS group), as an instrument for inducing remission of co-morbidities related...

Effect of sleeve gastrectomy on type 2 diabetes as an alternative treatment modality to Roux-en-Y gastric bypass: systemic review and meta-analysis.

Until recently, Roux-en-Y gastric bypass (RYGB) was the most frequently performed procedure in bariatric surgery. In the last decade, sleeve gastrectomy (SG) has emerged as a more popular, simpler, an...

Early increases in plasma bile acids post Roux-en-Y gastric bypass are driven by insulin sensitizing, secondary bile acids.

Roux-en-Y gastric bypass (RYGB) is the most effective treatment for morbid obesity and resolution of diabetes. Over the last decade it has become well-accepted that this resolution of diabetes occurs ...

Predictors of Remission of T2DM and Metabolic Effects after Laparoscopic Roux-en-y Gastric Bypass in Obese Indian Diabetics-a 5-Year Study.

Bariatric surgery has proven results for diabetes remission in obese diabetics. Despite this, a lot of ambiguity exists around patient selection. The objectives of this study are the following: (1) ev...

Clinical Trials [2756 Associated Clinical Trials listed on BioPortfolio]

Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity

The laparoscopic sleeve-gastrectomy (SG) compared to laparoscopic proximal Roux-Y-gastric bypass (PGB) is as successful in the treatment of morbid obesity in the majority of patients. In c...

Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass

Prospective randomized clinical trial aiming to compare laparoscopic Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) with primary outcome on excess weight loss, and secondary o...

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

This research project is designed to investigate endotoxin (a toxin present in the wall of certain kinds of bacteria) levels and the type of bacteria present in the intestine before and af...

Long or Very Long-Limb Gastric Bypass in Superobese

The goal of this study is to compare the clinical efficacy (weight loss and metabolic changes) of long (150 cm) versus very long (250cm) Roux alimentary limb gastric bypass in superobese...

Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)

Banded Versus Conventional Laparoscopic Roux-en-Y Gastric Bypass (GABY). The aim of this novel study is to evaluate, if an additional restrictive silastic ring can avoid dilation of the g...

Medical and Biotech [MESH] Definitions

Surgical procedure in which the STOMACH is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the SMALL INTESTINE by an end-to-side SURGICAL ANASTOMOSIS, depending on the amounts of intestinal surface being bypasses. This procedure is used frequently in the treatment of MORBID OBESITY by limiting the size of functional STOMACH, food intake, and food absorption.

A procedure consisting of the SURGICAL ANASTOMOSIS of the proximal part of the JEJUNUM to the distal portion of the ILEUM, so as to bypass the nutrient-absorptive segment of the SMALL INTESTINE. Due to the severe malnutrition and life-threatening metabolic complications, this method is no longer used to treat MORBID OBESITY.

The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

An inflatable device implanted in the stomach as an adjunct to therapy of morbid obesity. Specific types include the silicone Garren-Edwards Gastric Bubble (GEGB), approved by the FDA in 1985, and the Ballobes Balloon.

A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).


Advertisement
 

Relevant Topics

Endocrinology
Latest News Clinical Trials Research Drugs Reports Corporate
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Obesity
Latest News Clinical Trials Research Drugs Reports Corporate
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

Advertisement
 

Searches Linking to this Article